Erasca (ERAS) entered into an exclusive worldwide license agreement with Novartis (NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor with a potential profile in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors. To date, naporafenib has been dosed in over 500 patients across multiple trials and has demonstrated preliminary clinical proof-of-concept as well as favorable safety and tolerability data both as a single agent and in combination with other molecularly targeted and immuno-oncology therapies. As separately announced, Erasca has priced a $100M equity offering with select healthcare investors. Naporafenib is a potent and selective inhibitor of BRAF and CRAF. Safety, tolerability, and preliminary proof of concept of naporafenib alone or in combination have been shown in over 500 patients treated to date in NRASm melanoma and other RAS/MAPK pathway-driven tumors. Erasca plans to initially focus on advancing and securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnostic solid tumors as part of the planned Phase 2 SEACRAFT-1 trial and NRASm melanoma as part of the planned Phase 3 SEACRAFT-2 trial. Under the terms of the license agreement, in exchange for an exclusive worldwide license to develop and commercialize naporafenib, Erasca will pay to Novartis a one-time upfront cash payment of $20M and $80M of shares in Erasca common stock at a price of $6.50 per share. Novartis is eligible to receive up to $80M in cash upon the achievement of regulatory milestones covering two indications in the United States, Europe, and Japan, as well as up to $200M in cash upon the achievement of sales milestones. Novartis is also eligible to receive a low single-digit percentage royalty on net sales of naporafenib.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ERAS:
- Erasca Slides After Public Offering; Inks Licensing Deal with NVS
- Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
- Erasca Announces Pricing of Underwritten Offering of Common Stock
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination